The data showed that pretreatment of glioma cells with TRPA1 agonist increased pro-apoptotic protein (caspase-3/caspase-9, BAX) and decreased the level of anti-apoptotic protein (Bcl-2) compared to pre-treatment with the TRPA1 inhibitor (Fig. 4g-h). The gene discussed is TRPA1; the disease is central nervous system cancer.